Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Primary analysis of JUMP, a phase 3b, expanded-access study evaluating the safety and efficacy of ruxolitinib in patients with myelofibrosis, including those with low platelet counts.
Al-Ali HK, Griesshammer M, Foltz L, Palumbo GA, Martino B, Palandri F, Liberati AM, le Coutre P, García-Hernández C, Zaritskey A, Tavares R, Gupta V, Raanani P, Giraldo P, Hänel M, Damiani D, Sacha T, Bouard C, Paley C, Tiwari R, Mannelli F, Vannucchi AM. Al-Ali HK, et al. Among authors: bouard c. Br J Haematol. 2020 Jun;189(5):888-903. doi: 10.1111/bjh.16462. Epub 2020 Feb 4. Br J Haematol. 2020. PMID: 32017044 Free article. Clinical Trial.
Analysis of predictors of response to ruxolitinib in patients with myelofibrosis in the phase 3b expanded-access JUMP study.
Gupta V, Griesshammer M, Martino B, Foltz L, Tavares R, Al-Ali HK, Giraldo P, Guglielmelli P, Lomaia E, Bouard C, Paley C, Tiwari R, Zor E, Raanani P. Gupta V, et al. Among authors: bouard c. Leuk Lymphoma. 2021 Apr;62(4):918-926. doi: 10.1080/10428194.2020.1845334. Epub 2020 Nov 19. Leuk Lymphoma. 2021. PMID: 33210570 Free article. Clinical Trial.
Comparing the safety and efficacy of ruxolitinib in patients with Dynamic International Prognostic Scoring System low-, intermediate-1-, intermediate-2-, and high-risk myelofibrosis in JUMP, a Phase 3b, expanded-access study.
Passamonti F, Gupta V, Martino B, Foltz L, Zaritskey A, Al-Ali HK, Tavares R, Maffioli M, Raanani P, Giraldo P, Griesshammer M, Guglielmelli P, Bouard C, Paley C, Tiwari R, Vannucchi AM. Passamonti F, et al. Among authors: bouard c. Hematol Oncol. 2021 Oct;39(4):558-566. doi: 10.1002/hon.2898. Epub 2021 Jul 5. Hematol Oncol. 2021. PMID: 34224180 Free PMC article. Clinical Trial.
Harnessing orbital Hall effect in spin-orbit torque MRAM.
Gupta R, Bouard C, Kammerbauer F, Ledesma-Martin JO, Bose A, Kononenko I, Martin S, Usé P, Jakob G, Drouard M, Kläui M. Gupta R, et al. Among authors: bouard c. Nat Commun. 2025 Jan 2;16(1):130. doi: 10.1038/s41467-024-55437-x. Nat Commun. 2025. PMID: 39747072 Free PMC article.
[Cancer cell plasticity and metastatic dissemination].
Moyret-Lalle C, Pommier R, Bouard C, Nouri E, Richard G, Puisieux A. Moyret-Lalle C, et al. Among authors: bouard c. Med Sci (Paris). 2016 8-9;32(8-9):725-31. doi: 10.1051/medsci/20163208020. Epub 2016 Sep 12. Med Sci (Paris). 2016. PMID: 27615180 Free article. Review. French.
14 results